Knack Company Profile
What is the competitive landscape for KNACK
KNACK has seven approved drugs.
Drugs and US Patents for Knack
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Knack | LEVETIRACETAM | levetiracetam | INJECTABLE;INTRAVENOUS | 215465-001 | Dec 2, 2025 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Knack | PANTOPRAZOLE SODIUM | pantoprazole sodium | INJECTABLE;INTRAVENOUS | 214680-001 | May 19, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Knack | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | INJECTABLE;INJECTION | 220076-001 | Jul 22, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Knack | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | INJECTABLE;INJECTION | 213059-002 | Feb 15, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

